EVOLUS, INC. Deferred Offering Costs
EVOLUS, INC. (EOLS) had Deferred Offering Costs of $0 as of 2018-12-31, per its 10-K filed 2019-03-20.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2019-03-20
- 2018-12-31: Deferred Offering Costs $0.00.
- 2018-09-30: Deferred Offering Costs $0.00.
- 2018-06-30: Deferred Offering Costs $22.00K.
- 2018-03-31: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs | Deferred Offering Costs as first filed |
|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-03-20 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $22.00K 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $2.10M 10-K · filed 2019-03-20 | $2.13M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |